AICAR: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 8 sources cited

Overview

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also known as Acadesine) is a potent AMP-activated protein kinase (AMPK) activator that mimics the metabolic effects of endurance exercise at the cellular level. Originally developed as a cardioprotective agent for coronary bypass surgery, it gained widespread attention after a landmark 2008 study showed it improved running endurance by 44% in sedentary mice. Prohibited by the World Anti-Doping Agency as a metabolic modulator, it remains one of the most studied exercise-mimetic compounds in metabolic research.

Mechanism of Action

Once inside cells, AICAR is rapidly phosphorylated by adenosine kinase to ZMP (AICA ribotide, also known as 5-aminoimidazole-4-carboxamide ribotide). ZMP structurally mimics AMP and directly activates AMPK by binding to its γ-subunit, inducing a conformational change that promotes AMPK phosphorylation at Thr172 by upstream kinases (LKB1 and CaMKKβ). AMPK is the master metabolic energy sensor — when activated, it orchestrates a comprehensive shift from anabolic to catabolic metabolism. Key downstream effects include: stimulation of glucose uptake in skeletal muscle via GLUT4 translocation to the plasma membrane (insulin-independent); increased fatty acid oxidation through phosphorylation and inhibition of acetyl-CoA carboxylase (ACC), reducing malonyl-CoA and relieving CPT1 inhibition; enhanced mitochondrial biogenesis through PGC-1α activation; inhibition of mTORC1 signaling (reducing protein and lipid synthesis to conserve energy); and upregulation of genes associated with slow-twitch oxidative muscle fiber types. The net effect in cell and rodent studies is that cells behave as though they are energy-depleted and undergoing sustained aerobic exercise, burning fat, taking up glucose and building more mitochondria without physical exertion. A systematic review cautions that many AICAR effects once credited to AMPK are AMPK-independent, and in healthy men muscle AMPK phosphorylation did not rise during an infusion. However, AICAR also has direct effects on purine metabolism (it is an intermediate in the de novo purine synthesis pathway) and adenosine receptor modulation, contributing to its cardioprotective effects.

AICAR Benefits: What the Research Shows

  • The landmark 2008 study in Cell by Narkar et al. showed AICAR treatment improved treadmill running endurance by 44% in completely sedentary mice over 4 weeks, without any exercise training.
  • The same study reported that AICAR induced metabolic genes and shifted muscle toward a slow-twitch, oxidative endurance phenotype.
  • Clinical trials in coronary artery bypass surgery were mixed: an earlier trial found lower two-year mortality among the patients who suffered a post-reperfusion myocardial infarction, but the larger RED-CABG trial of 3,080 patients was stopped for futility and showed no reduction in death, stroke or severe left ventricular dysfunction.
  • AICAR-treated mice showed induction of oxidative metabolism genes and more oxidative muscle fibres in skeletal muscle.
  • The World Anti-Doping Agency prohibits AICAR as a metabolic modulator, listing it under activators of AMP-activated protein kinase alongside BAM15 and MOTS-c.
  • In ten men with type 2 diabetes, an intravenous AICAR infusion lowered blood glucose by reducing hepatic glucose output and also lowered plasma free fatty acids, which is why it was pursued as a diabetes treatment.

AICAR Dosage

  • Research subcutaneous dose: 150–500 mg daily, typically divided into morning and pre-workout administrations. The injectable form provides the most consistent bioavailability.
  • Clinical cardiac studies used intravenous infusion at 0.1 mg/kg/min for up to 7 hours during coronary artery bypass surgery.
  • Standard research cycle: 4–6 weeks on, 4 weeks off. Extended cycles increase the risk of metabolic disturbances.
  • Often stacked with GW501516 (Cardarine) in research settings for complementary endurance mechanisms — AICAR activates AMPK directly while GW501516 activates PPARδ. The pair has not been tested head to head against either compound alone.
  • Dose titration is critical: start at the lower end (150 mg) and increase gradually. Excessive AMPK activation can cause hypoglycemia, particularly in fasted individuals.
  • Take on training days 30–60 minutes before exercise for maximum synergistic effect with physical activity.
  • Blood glucose monitoring is recommended, especially during the first week and when combining with fasting or low-carbohydrate diets.
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

AICAR Side Effects & Safety

Known Side Effects

  • Hypoglycemia — the most significant acute risk, particularly in fasted states or combined with insulin-sensitizing agents. AMPK activation drives glucose uptake independently of insulin.
  • Lactic acidosis — excessive AMPK activation can shift metabolism in ways that promote lactate accumulation, particularly at high doses.
  • Gastrointestinal distress — nausea, cramping, and diarrhea reported at higher doses, likely related to AMPK activation in intestinal epithelium.
  • Potential muscle catabolism — AMPK activation inhibits mTORC1, which is essential for muscle protein synthesis. Prolonged high-dose use could theoretically impair muscle building.
  • Cardiac effects — while low-dose AICAR is cardioprotective, excessive adenosine receptor activation could theoretically cause bradycardia.
  • Unknown long-term effects on purine metabolism and uric acid levels, as AICAR is an intermediate in the purine synthesis pathway.

Safety Profile

AICAR has a reasonably well-characterized safety profile from clinical cardiac studies, where it was administered intravenously in controlled settings with good tolerability. However, the subcutaneous dosing protocols used in research settings are less well-studied in humans. The primary acute risk is hypoglycemia, which can be managed through glucose monitoring and appropriate carbohydrate intake. The risk increases significantly when combined with fasting, ketogenic diets, or other glucose-lowering agents. Contraindications include hypoglycemia-prone conditions (insulinoma, adrenal insufficiency), severe hepatic or renal impairment, and concurrent use of metformin or other AMPK-activating drugs (risk of excessive AMPK activation). The mTORC1 inhibition caused by AMPK activation means AICAR should be used cautiously by those seeking muscle hypertrophy — timing doses away from resistance training may mitigate this. Not recommended during pregnancy or in individuals under 18. WADA-tested athletes should be aware that AICAR is on the prohibited list as an AMPK activator.

What to Expect

Days 1–3: Increased warmth and subtle energy shift as AMPK activation begins modifying cellular metabolism. Blood glucose may dip lower than usual — have carbohydrates available. Some users notice enhanced aerobic capacity even in the first few sessions. Weeks 1–2: Endurance improvements become noticeable. Activities that previously caused fatigue feel easier. Fat oxidation increases, and some users notice reduced body fat, particularly with concurrent exercise. Appetite may decrease slightly. Weeks 3–4: Peak endurance effects. The 44% improvement in sedentary mice occurred over this timeframe. Active users report significantly improved cardiovascular performance, longer time to exhaustion, and improved recovery between sets/intervals. Weeks 5–6: Continued benefits with potential plateau. This is typically the endpoint of a cycle. Fat loss and endurance gains achieved during the cycle tend to partially persist after cessation, especially if exercise habits are maintained.

Common Stacks

Storage & Handling

Store lyophilized powder refrigerated at 36–46°F (2–8°C) or frozen at -4°F (-20°C) for long-term storage. Protect from light. After reconstitution with bacteriostatic water, refrigerate and use within 14–21 days. Do not freeze reconstituted solution. Shelf life of unreconstituted powder is approximately 24 months when stored at -20°C.

Pricing & Available Variants

$50price range
50mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

Related Peptides

Track AICAR in Your Protocol

Log your AICAR doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free